Drugs

  • Understanding dementia 7: Developing drug treatments

    Continuing our clinical teaching series, Dr Robert Tobiansky describes the many routes of current research and development in the search for a pharmacological treatment for dementia. Author/s: Robert Tobiansky For the full article please see the PDF download linked to the right. The full JDC archive is available if you subscribe....

    Restricted Content

    Most Journal articles are only accessible to Journal Subscribers. Some other content is only accessible to Society Members.

    Enable access

    Already a Society Member and/or a Journal Subscriber? Log in here

  • Understanding dementia 8: Other drugs aimed at reducing cognitive defects

    Dr Robert Tobiansky describes research into use of drugs acting on non-cholinergic neurotransmitter systems. Author/s: Robert Tobiansky For the full article please see the PDF download linked to the right. The full JDC archive is available if you subscribe....

    Restricted Content

    Most Journal articles are only accessible to Journal Subscribers. Some other content is only accessible to Society Members.

    Enable access

    Already a Society Member and/or a Journal Subscriber? Log in here

  • Why be a guinea pig?

    Now that Tacrine has been approved for use in France as well as the US, should you encourage people with dementia and their carers to take part in trials of other drugs? John Kellett believes there are good reasons to do so. Author/s: John Kellett For the full article please see the PDF download linked…...

    Restricted Content

    Most Journal articles are only accessible to Journal Subscribers. Some other content is only accessible to Society Members.

    Enable access

    Already a Society Member and/or a Journal Subscriber? Log in here

  • Developing a drug to treat dementia

    Palliative therapies are likely to precede disease-modifying agents by years or decades, but these earlydrugs will provide the tools for future medical research, writes Professor Peter Stonier. Author/s: Peter Stonier For the full article please see the PDF download linked to the right. The full JDC archive is available if you subscribe....

    Restricted Content

    Most Journal articles are only accessible to Journal Subscribers. Some other content is only accessible to Society Members.

    Enable access

    Already a Society Member and/or a Journal Subscriber? Log in here

  • Carers have different priorities

    Would a drug for dementia that produced modest improvement be worth using, despite side effects? Carers’ views contrast sharply with those of professionals on this question, as Antony Bayer’s research showed. Author/s: Antony Bayer For the full article please see the PDF download linked to the right. The full JDC archive is available if you…...

    Restricted Content

    Most Journal articles are only accessible to Journal Subscribers. Some other content is only accessible to Society Members.

    Enable access

    Already a Society Member and/or a Journal Subscriber? Log in here